Advertisement
![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
Collaboration › Details
Affimed–Noble Financial Capital Markets: investor conference, 201601 supply service Affimed NV presents at NobleCon12 Annual Investor Conference
![]() |
Period | 2016-01-19 |
![]() |
Partner, 1st | Affimed N.V. (Nasdaq: AFMD) |
Group | Affimed (Group) | |
Partner, 2nd | Noble Financial Capital Markets | |
![]() |
Product | NobleCon12 Investor Conference 2016 Sandpiper Bay |
Product 2 | TandAb bispecific antibody | |
![]() |
Person | Fischer, Florian (MedVenture Partners 201305 Managing Director + Affimed CFO 201510) |
Affimed N.V.. (1/12/16). "Press Release: Affimed to Present at Noble Financial Capital Markets’ 12th Annual Investor Conference". Heidelberg.
Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that its CFO, Florian Fischer, will present at the NobleCon12 - Noble Financial Capital Markets’ 12th Annual Investor Conference at Club Med in Sandpiper Bay, Florida, on Tuesday, January 19 at 11:30 am Eastern Standard Time.
Following the conference on January 22, 2016, a high-definition video webcast of Affimed’s presentation and a copy of the presentation materials will be available on the Company's website, www.affimed.com, or as part of a complete catalog of presentations available on the Noble Financial websites: www.noblefcm.com, or www.nobleconference.com. A Microsoft SilverLight viewer (a free download from the presentation link) will be required to participate. The webcast and presentation will be archived on the company's website and on the Noble websites for 90 days following the event.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed’s product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed’s proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit www.affimed.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the risk of cessation or delay of any of the ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors described under the heading "Risk Factors" in Affimed’s filings with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.
Contact:
Affimed N.V.
Caroline Stewart, Head IR & Communication Phone: +1 347394 6793 E-Mail: IR@affimed.com or c.stewart@affimed.com
Media requests:
Stephanie May or Gretchen Schweitzer
MacDougall Biomedical Communications
Phone: +49 89 2424 3494 or
+49 172 861 8540
E-Mail: gschweitzer@macbiocom.com
Record changed: 2017-04-02 |
Advertisement
![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
More documents for Affimed (Group)
- [1] Affimed N.V.. (5/29/19). "Press Release: Affimed to Present at the Jefferies 2019 Healthcare Conference". Heidelberg....
- [2] Affimed N.V.. (5/22/19). "Press Release: Affimed Announces R&D Strategy to Focus on Innate Immunity Portfolio, Reports First Quarter 2019 Financial Results and Operational Progress". Heidelberg....
- [3] Affimed N.V.. (4/17/19). "Press Release: Affimed Provides Regulatory Update on AFM11 Clinical Program". Heidelberg....
- [4] Affimed N.V.. (4/1/19). "Press Release: Affimed Highlights AFM24 Innate Cell Engager Novel Mechanism of Action and Potential for the Treatment of EGFR-expressing Solid Tumors at the American Association for Cancer Research (AACR) 2019 Annual Meeting". He...
- [5] Affimed N.V.. (3/19/19). "Press Release: Affimed Announces Milestone Payment from Genentech and ROCK Platform Presentation at Innate Killer Summit 2019, Further Highlighting Leadership in Innate Immunity". Heidelberg....
- [6] Affimed N.V.. (1/4/19). "Press Release: Affimed to Present at the 37th Annual J.P. Morgan Healthcare Conference". Heidelberg....
- [7] Affimed N.V.. (10/8/18). "Press Release: Affimed Places AFM11 (CD19/CD3-Targeting T cell Engager) Phase 1 Program on Clinical Hold". Heidelberg....
- [8] Affimed N.V.. (8/30/18). "Press Release: Affimed to Present at the 2018 Wells Fargo Securities Healthcare Conference". Heidelberg....
- [9] Affimed N.V.. (8/27/18). "Press Release: Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets". Heidelberg....
- [10] Affimed N.V.. (5/3/18). "Press Release: Affimed Introduces ROCK Platform for Tailored Immune Cell Engagers". Heidelberg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top